Cutaneous Psoriasis
Introduction
Background
Cutaneous psoriasis (PS) is a chronic inflammatory disease primarily affecting the skin. It impacts approximately 2–3% of the population, making it a common condition globally. [1] The disease is characterized by thick, red, scaly patches on the skin, often accompanied by itching and discomfort. A significant proportion of individuals with psoriasis, estimated between 10% and 30%, also develop psoriatic arthritis (PSA), a debilitating autoimmune disease that affects the joints and belongs to the family of spondyloarthritides. [1] Psoriasis and psoriatic arthritis are considered interrelated disorders, with the prevalence of psoriasis being substantially higher among first-degree relatives of individuals with psoriatic arthritis compared to the general population. [1]
Biological Basis
The development of psoriasis is a complex process involving interactions between genetic predisposition and environmental risk factors. [1] It is an inflammatory disease, and genetic studies have consistently identified the Major Histocompatibility Complex (MHC) class I region, also known as PSORS1 (psoriasis susceptibility locus 1), as a primary and highly significant genetic risk factor. [1] Genetic variation in the MHC (multiple histocompatibility locus antigen cluster) increases the risk of developing psoriasis. However, only a minority of individuals with this risk factor develop the disease, indicating the involvement of other genetic influences and environmental triggers. [1] Recent genome-wide association studies (GWAS) have confirmed associations with immune-related genes such as IL23R (interleukin 23 receptor) and IL12B (interleukin 12B) in both psoriasis and psoriatic arthritis, and have also identified new susceptibility loci. [1]
Clinical Relevance
Psoriasis and psoriatic arthritis are common inflammatory diseases affecting the skin and joints. [1] Understanding the genetic factors involved in these conditions is crucial for elucidating their pathogenesis and identifying novel drug targets. [1] Genetic research, particularly through large-scale genome-wide association studies, continues to enhance the understanding of the underlying biological mechanisms, which can lead to improved diagnostic methods and more effective therapeutic strategies for these conditions.
Social Importance
As a chronic and often visible skin condition, cutaneous psoriasis can significantly impact an individual's quality of life, affecting their physical comfort, emotional well-being, and social interactions. The debilitating nature of associated psoriatic arthritis further adds to the burden on affected individuals. [1] Given its prevalence and potential for severe impact, research into the genetic and biological basis of psoriasis is vital for developing better treatments and ultimately improving the lives of millions affected worldwide.
Methodological and Statistical Constraints
The ability to comprehensively identify all genetic factors contributing to cutaneous psoriasis is significantly impacted by statistical and methodological limitations inherent in genome-wide association studies (GWAS). Both the discovery and replication cohorts in these studies, despite their scale, were noted to be insufficient in size to identify the majority of genetic factors or low-risk variants associated with psoriasis and psoriatic arthritis. [1] This limitation means that numerous true genetic associations, especially those with smaller effect sizes, may have been missed, as evidenced by known susceptibility SNPs, such as IL23R R381Q, not reaching statistical significance in the initial discovery phase. [1] The presence of borderline P values for other SNPs also suggests a potential underestimation of disease-contributing variants, highlighting the need for increased statistical power through larger sample sizes. [1]
Furthermore, the methodologies employed introduced specific constraints on data interpretation and confidence. One study's initial association scan utilized pooled DNA samples, a cost-efficient approach that inherently prevented crucial quality control measures like the analysis of Hardy-Weinberg equilibrium. [2] This necessitates that such findings be regarded as preliminary, requiring validation through individual genotyping of significant markers. [2] Concerns about effect size inflation for top-ranked associated markers are also acknowledged, potentially overestimating the true genetic impact of some identified variants. [2] Additionally, the reliance on a subset of available SNPs in GWAS platforms means that some disease-contributing genes might be missed due to incomplete genomic coverage. [3]
Population Specificity and Generalizability
A major limitation affecting the broader applicability of the findings is the exclusive focus on populations of European descent in both discovery and replication cohorts. [1] While this approach helps control for population stratification within the studied groups, it severely restricts the generalizability of the identified genetic associations to individuals of other ancestries. Genetic architectures, including allele frequencies and linkage disequilibrium patterns, can vary significantly across different ethnic populations, meaning that susceptibility loci identified in European cohorts may not be relevant or may manifest differently in other global populations.
Despite efforts to account for population substructure using methods like genomic control and EIGENSTRAT, the inherent complexity of European population substructure, characterized by clusters of northern and southern populations, remains a potential confounder. [1] Such substructure, if not perfectly adjusted for, could lead to spurious associations. Moreover, the ascertainment of control groups presents a potential bias; some studies utilized random controls for whom specific information about autoimmune or inflammatory diseases was unavailable. [1] While authors suggest a modest effect on power, the possibility of misclassified controls, who might unknowingly carry undiagnosed conditions, could dilute true genetic associations and impact the accuracy of effect estimates.
Disease Heterogeneity and Unaccounted Factors
Psoriasis and psoriatic arthritis are recognized as complex inflammatory diseases, a characteristic that introduces challenges in fully elucidating their genetic underpinnings. The studies acknowledge that the disease etiology involves "overlapping subsets of risk factors" and that genetic effects may not be purely additive. [1] This complexity implies that simple genetic models might not capture intricate gene-gene interactions (epistasis) or gene-environment interactions, which are crucial components of complex disease susceptibility and contribute to the phenomenon of "missing heritability."
The broad phenotypic definition of cutaneous psoriasis encompasses various subtypes and severities, which, if not precisely stratified, can introduce heterogeneity within case cohorts and complicate the identification of specific genetic markers. For instance, some patient cohorts were recruited from rehabilitation hospitals, potentially biasing the sample towards more severe or chronic forms of the disease. [2] Furthermore, the practice of pooling sexes for genetic analyses means that gender-specific genetic effects, where certain SNPs might be associated with psoriasis only in males or females, could be overlooked and remain undetected. [3] These unmeasured or unstratified factors limit the comprehensive understanding of disease mechanisms and the full spectrum of genetic contributions.
Definition and Nature of Cutaneous Psoriasis
Cutaneous psoriasis, often abbreviated as PS, is precisely defined as a chronic inflammatory disease primarily affecting the skin, characterized by its immune-mediated pathogenesis. [2] This condition is prevalent, affecting approximately 2–3% of the general population. [1] As a multifactorial trait, its inheritance involves complex interactions between multiple genetic and environmental risk factors. [2] An important aspect of its conceptual framework is its interrelation with psoriatic arthritis (PSA), a debilitating autoimmune disease belonging to the family of spondyloarthritides, which develops in about 25% of psoriasis patients. [1] The strong association between these two disorders is underscored by a 19-fold higher prevalence of psoriasis among first-degree relatives of individuals with psoriatic arthritis compared to the general population. [1]
Genetic Classification and Nomenclature
The nosological system for psoriasis includes specific terminology to denote its genetic underpinnings. A primary disease susceptibility locus, PSORS1 (Psoriasis Susceptibility Locus 1), is strongly associated with the MHC class I region, an association first identified in the 1970s and repeatedly confirmed. [2] Beyond PSORS1, other susceptibility loci have been identified, such as PSORS4, which encompasses the late cornified envelope gene cluster (LCE) within the Epidermal Differentiation Complex. [1] Genetic studies have further expanded the classification of psoriasis-associated genes, including IL23R and IL12B, which have been convincingly identified as disease susceptibility genes. [4] More recently, ZNF313/RNF114 has been characterized as a novel psoriasis susceptibility gene, contributing to the evolving understanding of its genetic landscape. [2] Additional identified loci include a region on chromosome 4q27 harboring IL2 and IL21 genes, and a region on 15q21 that contains SPPL2A. [1]
Diagnostic and Research Criteria
While specific clinical diagnostic criteria such as lesion morphology or histological findings are not detailed, research criteria for patient ascertainment are established for genetic studies. Individuals are typically diagnosed with psoriasis or psoriatic arthritis for inclusion in case cohorts, often recruited from dermatology clinics or rehabilitation hospitals. [2] For genetic analyses, operational definitions involve the genotyping of DNA samples from affected individuals and healthy controls, with DNA quantification typically performed using methods like Quanti-iT Picogreen. [2] Genome-wide association studies (GWAS) employ statistical thresholds, such as P-values less than 5x10^-5, to identify significant genetic associations, thereby establishing research criteria for identifying susceptibility loci and informing the conceptual frameworks of disease etiology. [1] This categorical approach in genetic research distinguishes between affected cases and unaffected controls, with careful matching for factors like ethnicity and geographical origin. [2]
Genetic Predisposition and Immune System Dysregulation
Cutaneous psoriasis is fundamentally a multifactorial disease with a strong inherited component, consistently observed through its familial recurrence. The most significant genetic determinant is the primary disease susceptibility locus, PSORS1, located within the Major Histocompatibility Complex (MHC) class I region on chromosome 6p21. Genetic variations in the MHC are recognized as the predominant risk factor for psoriasis, playing a substantial role in its development, although they do not fully explain every case . [1], [2]
Beyond the MHC, numerous other genes contribute to the complex polygenic risk profile of psoriasis. Genome-wide association studies have identified several key genes involved in immune regulation, including IL23R and IL12B, which are crucial for the interleukin-23/interleukin-12 signaling pathway that mediates immune cell communication and inflammation . [1], [4], [5] Other associated loci include a putative RUNX1 binding site variant, the late cornified envelope (LCE) gene cluster (PSORS4), and a region on 15q21 that harbors SPPL2A, a gene involved in activating tumor necrosis factor-alpha and stimulating IL12 expression in dendritic cells . [1], [6] Additionally, ZNF313/RNF114 has been identified as a novel susceptibility gene, coding for a protein that binds ubiquitin, suggesting its involvement in modulating immune responses. [2] These diverse genetic contributions collectively underscore the intricate immune-mediated inflammatory nature of psoriasis.
The Interplay of Genetics and Environmental Triggers
The development of cutaneous psoriasis is not solely determined by an individual's genetic makeup; it is critically influenced by an interaction between genetic predisposition and various environmental risk factors. This gene-environment interplay is highlighted by the observation that only approximately 10% of individuals who possess the primary MHC genetic risk factor actually develop psoriasis. This statistic indicates that additional genetic modifiers and external environmental triggers are essential for the disease to manifest. [1]
Environmental triggers are considered pivotal in initiating or exacerbating the inflammatory cascade in genetically susceptible individuals. While studies emphasize the general importance of these triggers, specific details regarding particular lifestyle choices, dietary components, or distinct environmental exposures are not extensively detailed in the provided context. The combined effect of an individual's genetic vulnerabilities and their exposure to specific environmental factors is a key aspect of the complex etiology of psoriasis, ultimately leading to the characteristic chronic inflammatory skin condition.
Shared Genetic Pathways with Autoimmune Conditions
Psoriasis frequently co-occurs within a broader spectrum of inflammatory and autoimmune diseases, suggesting shared underlying genetic predispositions. Psoriatic arthritis (PSA), a debilitating autoimmune condition affecting the joints, is closely linked with psoriasis, with a significantly elevated prevalence of psoriasis among first-degree relatives of individuals with PSA when compared to the general population. [1]
Further evidence for these shared genetic pathways comes from the identification of common susceptibility loci that contribute to multiple autoimmune diseases. For example, a novel genetic locus on chromosome 4q27, which contains the IL2 and IL21 genes, has been associated with psoriasis as well as other autoimmune disorders such as Celiac disease, Type 1 diabetes, Grave’s disease, and Rheumatoid Arthritis. [1] This overlap suggests that certain genetic variations confer a general susceptibility to immune dysregulation, which can manifest as psoriasis or other autoimmune conditions depending on the specific genetic profile and environmental interactions.
Biological Background
Psoriasis is a chronic inflammatory disease primarily affecting the skin, impacting 2–3% of the population, and is considered an immune-mediated disorder. [1] This complex condition, which often presents with genetic predisposition and environmental triggers, can also manifest as psoriatic arthritis (PSA) in about 25% of affected individuals, highlighting an intricate interplay between genetic factors, immune system dysregulation, and cellular processes. [1]
Genetic Predisposition and Immune System Regulation
Genetic factors play a significant role in susceptibility to psoriasis, with the Major Histocompatibility Complex (MHC) Class I region, also known as PSORS1, identified as a primary and most important genetic risk factor. [1] While this region strongly influences psoriasis risk, its association with psoriatic arthritis is less pronounced. [1] Beyond the MHC, variants in genes such as IL12B and IL23R, which encode components of critical immune signaling pathways, have been consistently identified as psoriasis-risk genes, with specific sequence variants in these genes even conferring protection against the condition. [1] Other susceptibility loci include a putative RUNX1 binding site variant located between SLC9A3R1 and NAT9, and a novel gene, ZNF313/RNF114, which encodes an E3 ubiquitin ligase that positively regulates T cell activation. [1] The ubiquitylation process itself is crucial for diverse cellular functions, including transcriptional activation, endocytosis, and signaling, underscoring the broad impact of such genetic variations on immune cell behavior and overall disease pathogenesis. [2]
Cellular Signaling and Inflammatory Pathways
The pathogenesis of psoriasis is deeply rooted in dysregulated cellular signaling and inflammatory pathways, particularly those involving interleukins and various immune cells. Key cytokines like IL-12 and IL-23 are central to the inflammatory cascade, with the IL12B gene encoding a subunit shared by both IL-12 and IL-23, and IL23R encoding the IL-23 receptor. [1] These pathways are critical for the differentiation and function of T Helper 17 (Th17) cells, which are significant contributors to psoriatic inflammation. [1] Additionally, IL-6 plays a role in programming Th17 cell differentiation by promoting the sequential engagement of the IL-21 and IL-23 pathways, while interleukin-2 signaling, mediated by STAT5, conversely acts to constrain Th17 cell generation. [1] The enzyme SPPL2A (signal peptide peptidase like 2a) further contributes to this inflammatory environment by catalyzing the intramembrane cleavage of TNFA, a process that triggers IL12 expression in activated human dendritic cells. [1]
Epidermal Homeostasis and Tissue Dysregulation
Psoriasis manifests as a disruption in the normal homeostasis of the epidermis, the outermost layer of the skin, characterized by hyperproliferation and abnormal differentiation of keratinocytes. The late cornified envelope gene cluster (LCE), located within the Epidermal Differentiation Complex (PSORS4), is associated with psoriasis susceptibility and plays a role in epidermal differentiation. [1] The ADAM33 gene, a new candidate for psoriasis susceptibility, encodes an ADAM protease that is involved in protein maturation and localization, potentially influencing cellular adhesion and signaling within the skin. [1] Furthermore, the protein SPPL2A is profoundly stained throughout the epidermis and in some dermal cells in both lesional and non-lesional skin, suggesting its widespread involvement in skin cell function and the inflammatory response. [1] Another intriguing finding is the presence of a processed pseudogene for USP8 (ubiquitin-specific protease-8) located upstream from HLA-C, indicating potential regulatory interactions between ubiquitin-mediated processes and immune responses in the skin. [1]
Interconnectedness with Systemic Autoimmunity
Psoriasis and psoriatic arthritis are not isolated conditions but are interconnected with a broader spectrum of autoimmune diseases, sharing common genetic susceptibilities and underlying immunological mechanisms. A novel locus identified on chromosome 4q27, which harbors the interleukin 2 (IL2) and interleukin 21 (IL21) genes, highlights this systemic interconnectedness. [1] This particular genomic region has also been associated with other autoimmune conditions such as Celiac disease, Type 1 diabetes, Grave’s disease, and Rheumatoid Arthritis, suggesting common genetic pathways that predispose individuals to multiple immune-mediated disorders. [1] The pathogenic role of IL-21 in a lupus-prone mouse model further supports its broad relevance in autoimmune pathology, where its blockade can reduce disease progression. [1] This shared genetic landscape emphasizes that the immune dysregulation observed in psoriasis is often part of a wider systemic vulnerability to autoimmunity.
Immune Signaling and Cytokine Networks
Cutaneous psoriasis is characterized by dysregulated immune cell signaling, particularly involving T helper 17 (Th17) cells and their associated cytokines. Genetic variants in the IL12B gene, which encodes the p40 subunit common to both IL-12 and IL-23, and the IL23R gene, encoding the receptor for IL-23, are strongly associated with psoriasis susceptibility ,. [1] For example, the IL23R R381Q SNP and specific polymorphisms within IL12B, including rs3212227 and rs6887695, are associated with disease susceptibility and may confer protection against psoriasis . [1], [2], [4] These genes are crucial for understanding disease mechanisms and for identifying novel therapeutic targets [1] suggesting that genetic profiling of these pathways could potentially predict response to biologics targeting IL-12/IL-23, or influence the propensity for immune-related adverse reactions, although specific pharmacogenetic links to drug response require further elucidation. The Major Histocompatibility Complex (MHC) Class I region, which includes the highly associated SNP rs10484554, also exhibits the strongest genetic association with psoriasis [1] underscoring its role in immune regulation and potential implications for drug immunogenicity or hypersensitivity reactions.
Novel Susceptibility Genes and Potential Therapeutic Implications
Beyond established immune pathways, genome-wide association studies have uncovered novel genetic loci associated with psoriasis susceptibility, providing new insights into disease biology and potential avenues for drug development. For instance, ZNF313/RNF114 has been identified as a novel psoriasis susceptibility gene. [2] This gene encodes a C3HC4 RING domain protein that binds ubiquitin, suggesting a role in protein ubiquitination and cellular signaling pathways [2] with allele frequencies of rs495337 influencing gene expression. [2] Other novel loci include variants in the conserved oligomeric golgi complex component 6 (COG6) gene region, such as rs7993214, and an intergenic region between granulysin (GNLY) and atonal (ATOH) on chromosome 2p11, exemplified by rs2164807. [1] While direct pharmacogenetic data linking these novel susceptibility genes to specific drug responses are not yet available, their identification helps to expand the understanding of psoriasis pathogenesis, which in turn could lead to the discovery of entirely new drug targets and the development of personalized therapies based on an individual's unique genetic profile.
Clinical Utility of Psoriasis-Associated Genetic Markers
The identification of genetic markers associated with cutaneous psoriasis, particularly those involved in key pathogenic pathways, holds significant promise for advancing personalized medicine. Understanding an individual's genetic predisposition, including variants in IL23R, IL12B, and the MHC class I region, provides a foundational framework for future clinical applications. [1] While current research primarily focuses on disease susceptibility, these genetic insights are instrumental in deciphering disease mechanisms and pinpointing novel drug targets. [1] In the future, pharmacogenetic testing for these markers could potentially guide drug selection, enabling clinicians to identify patients most likely to respond to specific pathway-targeted therapies or those at higher risk for certain adverse drug reactions. Ultimately, the integration of such pharmacogenetic information into clinical guidelines could facilitate more precise and effective personalized prescribing strategies, optimizing treatment outcomes and enhancing patient safety in cutaneous psoriasis management.
Key Variants
| RS ID | Gene | Related Traits |
|---|---|---|
| rs10484554 | LINC02571 - HLA-B | AIDS cutaneous psoriasis measurement psoriasis psoriasis, type 2 diabetes mellitus |
| rs17728338 | TNIP1 - ANXA6 | psoriasis cutaneous psoriasis measurement atopic eczema, psoriasis |
| rs2082412 | UBLCP1 - IL12B | cutaneous psoriasis measurement psoriasis |
| rs610604 | TNFAIP3 | cutaneous psoriasis measurement psoriasis vulgaris psoriasis psoriasis, type 2 diabetes mellitus myeloid leukocyte count |
| rs191667458 | USP49 | cutaneous psoriasis measurement |
| rs20541 | IL13, TH2LCRR | psoriasis cutaneous psoriasis measurement serum IgE amount Hodgkins lymphoma asthma |
| rs12895275 | RGS6 | cutaneous psoriasis measurement |
| rs17052344 | UBBP4, UBBP4 | cutaneous psoriasis measurement |
| rs7922314 | ALDH7A1P4 - ADO | cutaneous psoriasis measurement |
| rs4795067 | NOS2 | psoriasis cutaneous psoriasis measurement psoriatic arthritis |
References
[1] Liu Y, et al. "A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci." PLoS Genet, vol. 4, no. 3, 2008, p. e1000041.
[2] Capon F, et al. "Identification of ZNF313/RNF114 as a novel psoriasis susceptibility gene." Hum Mol Genet, vol. 17, no. 10, 2008, pp. 1493-500.
[3] Yang Q, et al. "Genome-wide association and linkage analyses of hemostatic factors and hematological phenotypes in the Framingham Heart Study." BMC Med Genet, vol. 8, 2007, p. 64.
[4] Cargill, M, et al. “A Large-Scale Genetic Association Study Confirms IL12B and Leads to the Identification of IL23R as Psoriasis-Risk Genes.” American Journal of Human Genetics, vol. 80, 2007, pp. 273–290.
[5] Capon, F, et al. “Sequence Variants in the Genes for the Interleukin-23 Receptor (IL23R) and Its Ligand (IL12B) Confer Protection against Psoriasis.” Human Genetics, vol. 122, 2007, pp. 201–206.
[6] Helms, C, et al. “A Putative RUNX1 Binding Site Variant between SLC9A3R1 and NAT9 Is Associated with Susceptibility to Psoriasis.” Nature Genetics, vol. 35, 2003, pp. 349–356.